

# Isopsoralen ameliorates H<sub>2</sub>O<sub>2</sub>-induced damage in osteoblasts via activating the Wnt/ $\beta$ -catenin pathway

YU-PENG LI, BIN WU, JIE LIANG and FEI LI

Department of Orthopedics, The People's Hospital of China Three Gorges University, Yichang, Hubei 443000, P.R. China

Received July 23, 2018; Accepted May 16, 2019

DOI: 10.3892/etm.2019.7741

**Abstract.** Osteoporosis is a disease with a worldwide prevalence that involves a severe loss of bone mineral density and decreased microarchitecture, which increases the risk of bone fracture. The present study evaluated the effects of isopsoralen on osteoblastic OB-6 cells following hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced damage and investigated the molecular mechanisms involved in this process. For *in vitro* experiments, OB-6 osteoblasts were treated with H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub> + isopsoralen then the cell viability, apoptosis, reactive oxygen species (ROS) production and calcium accumulation were determined. Results demonstrated that treatment with H<sub>2</sub>O<sub>2</sub> reduced cell viability, runt-related transcription factor 2 (RUNX2) and osteocalcin (OCN) expression levels, and calcium deposition, whilst markedly increasing cell apoptosis and ROS production. However, isopsoralen (1  $\mu$ M) provided significant protection against H<sub>2</sub>O<sub>2</sub>-induced alterations in osteoblasts. In addition, isopsoralen effectively upregulated protein expression of tankyrase and  $\beta$ -catenin which are the main transducers of the Wnt/ $\beta$ -catenin pathway. Of note, the protective effects of isopsoralen against H<sub>2</sub>O<sub>2</sub>-induced damage were attenuated in OB-6 cells treated with tankyrase inhibitor XAV-939. In conclusion, the present findings provided evidence that isopsoralen attenuated oxidative stress-induced injury in osteoblasts via the Wnt/ $\beta$ -catenin signaling pathway.

## Introduction

Osteoporosis is a skeletal disease where systemic destruction of bone mass and microarchitecture occurs, which often increases the risk of bone fractures and other complications (1,2). Osteoporosis typically affects the elderly, with women more at risk, and the disease negatively impacts the patient's quality of life (3). There is a direct link between

osteoporosis and menopause (4), whilst one in five men will suffer from osteoporotic fracture during their lifetime (5). Therefore, the treatment of osteoporosis has attracted intensive attention worldwide.

To date, teriparatide, strontium and bisphosphonates have been widely used for the treatment of osteoporosis by reducing bone resorption and increasing bone formation (6); however, these synthetic medicines have several side-effects (7). Therefore, novel, more effective and safer agents that can be used for the treatment of osteoporosis are highly required. Notably, isopsoralen and its isoformer psoralen are isolated from a number of fruits, vegetables and traditional Chinese medicines (8,9), and they both display antiosteoporotic effects in ovariectomy-induced osteoporotic rats (10) and *in vitro* (11). In addition, isopsoralen demonstrates osteoprotective effects as well as stimulatory effects on bone formation (12,13) through increasing strength of trabecular bone microstructure (14), inducing apoptosis or necrosis of osteosarcoma (15) and promoting the differentiation of bone marrow stromal stem cells (BMSCs) into osteoblasts (16). However, the underlying osteoprotective mechanisms of isopsoralen have not been widely investigated.

The Wnt/ $\beta$ -catenin signaling pathway is a conserved signaling pathway with its signal transduced by  $\beta$ -catenin and tankyrase proteins (17,18). The alterations of Wnt/ $\beta$ -catenin activity are often associated with developmental disorders and diseases such as cancer, neuronal diseases and skeletal disorders (19). Increasing evidence indicates that the Wnt/ $\beta$ -catenin signaling pathway is involved in the regulation of osteogenesis and bone formation (20,21). **In the present study, the protective effects and mechanisms of isopsoralen on oxidative stress-induced osteoblastic OB-6 cells were investigated. Results suggested that isopsoralen could ameliorate oxidative stress-induced damage through the Wnt/ $\beta$ -catenin signaling pathway, indicating that isopsoralen may be a novel treatment approach for osteoporosis.**

## Materials and methods

**Cell culture and treatments.** OB-6 osteoblastic cells (Cell Bank of Shanghai Institute of Biological Science) were cultured in  $\alpha$ -minimum essential medium ( $\alpha$ -MEM; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Inc.), and incubated at 37°C

---

Correspondence to: Dr Yu-Peng Li, Department of Orthopedics, The People's Hospital of China Three Gorges University, 4 Hudi Street, Yichang, Hubei 443000, P.R. China  
E-mail: liyupeng17@sina.com

**Key words:** isopsoralen, oxidative stress, osteoblast, Wnt/ $\beta$ -catenin pathway

with 5% CO<sub>2</sub>. OB-6 cells were divided into four groups including the control group with  $\alpha$ -MEM only, an isoporsoralen group treated with 1  $\mu$ M isoporsoralen (Shanghai Meilun Biotechnology Co., Ltd.) for 12, 24 and 48 h, a hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) group treated with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 12, 24 and 48 h or a isoporsoralen + H<sub>2</sub>O<sub>2</sub> group pretreated with 1  $\mu$ M isoporsoralen and 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 12, 24 and 48 h. Subsequently, cell viability, apoptosis, runt-related transcription factor (RUNX2) and osteocalcin (OCN) expression, reactive oxygen species (ROS) production, mitochondrial respiratory chain complex I activity, tankyrase protein expression, Wnt3,  $\beta$ -catenin, and calcium accumulation were analyzed, as described below.

**Cell viability assay.** OB-6 osteoblastic cells at a density of 5x10<sup>3</sup> cells/ml were seeded in 96-well plates and cultured in  $\alpha$ -MEM with 1  $\mu$ M isoporsoralen, 100  $\mu$ M hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) or 1  $\mu$ M isoporsoralen + 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>. Following 12, 24, 48 h of culture, cell viability was evaluated using 2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2-tetrazolium 5-carboxanilide (XTT, Sigma-Aldrich; Merck KGaA) method in accordance with a previous report (10). Each experiment was performed in triplicate and repeated four times.

**Flow cytometry.** Cells at a density 5x10<sup>3</sup> cells/ml were seeded in a 96-well plate, then treated with H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M) or isoporsoralen (1  $\mu$ M) + H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M) for 12, 24 and 48 h. Cell apoptotic rate was measured by flow cytometry according to the manufacturer's instructions. In brief, OB-6 osteoblastic cells were collected and fixed in 70% ethanol for 30 min at room temperature. Cells were stained with Annexin V-fluorescein isothiocyanate/propidium iodide (50  $\mu$ g/ml) using an Annexin V-FITC Apoptosis Detection kit (Roche Molecular Diagnostics) prior to analysis using a FACScanVantage™ SE (BD Biosciences, San Jose, CA, USA). Each experiment was performed in triplicate and repeated four times and data were analyzed using the FloJo software version 10.1.1 (FlowJo, LLC).

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** RT-qPCR was used to determine OCN and RUNX2 mRNA expression. Total cellular RNA was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific) and cDNA synthesis was performed using TaKaRa PrimeScript II 1st Strand cDNA Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.). qPCR was performed using the SYBR PrimeScript RT-PCR kit (Takara Bio, Inc.) in an Applied Biosystems 7500 Fluorescent Quantitative PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 40 cycles at 94°C for 5 min, 94°C for 30 sec and 58°C for 1 min. The following primers were provided by Sangon Biotech Co., Ltd.: OCN forward, 5'-CATGAGCCCTCACTCT-3' and reverse, 5'-AGAGCGACACCCTAGAC-3'; RUNX2 forward, 5'-AGCCTCTTCAGCGCAGTGAC-3' and reverse, 5'-CTGGTGCTCGATCCCAA-3' and GAPDH forward, 5'-AACGGATTTGGTCGTATTGGG-3' and reverse, 5'-CCTGGAAGATGGTGATGGGAT-3'. Each experiment was performed in triplicate and repeated four times. The 2<sup>- $\Delta\Delta$ Cq</sup> method was used to quantify the data (22).

**Western blot analysis.** Western blotting was used to determine the protein expression levels of tankyrase, Wnt3 and  $\beta$ -catenin in accordance to a previous study (11). Total protein was extracted from cells using RIPA lysis buffer (Beyotime Institute of Biotechnology) and their concentrations were determined using the BCA method. A total of 20  $\mu$ g protein was separated using 10% SDS-PAGE and transferred to PVDF membranes. The membranes were subsequently blocked with 5% non-fat milk for 2 h at room temperature and incubated at 4°C overnight with primary antibodies against tankyrase (1:2,500; cat. no. sc-365897; Santa Cruz Biotechnology Inc.) Wnt3 $\alpha$  (1:2,500; cat. no. 2391; Santa Cruz Biotechnology Inc.),  $\beta$ -catenin (1:1,000; cat. no. 8480; Cell Signaling Technology, Inc.) and  $\beta$ -actin (1:2,500; cat. no. sc-47778; Santa Cruz Biotechnology Inc.). Finally, membranes were incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:5,000; cat. no. 7074; Cell Signaling Technology, Inc.) at 37°C for 1 h. Image J2X software version 2.1.4.7 (Rawak Software, Inc.) was used to determine protein band density. Each experiment was performed in triplicate and repeated three times.

**Calcium accumulation.** Calcium Colorimetric Assay kits (cat. no. MAK022; Sigma-Aldrich; Merck KGaA) were used to measure calcium deposition (expressed as  $\mu$ g/mg cellular protein) according to the manufacturer's instructions. Each experiment was performed in triplicate and repeated three times.

**ROS production.** Intracellular ROS production was measured using a CellROX™ Green Reagent (cat. no. C10444; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's guidelines. ROS levels were measured with a FACSCalibur™ flow cytometer (BD Biosciences) with the excitation source at 488 nm and emission at 525 nm. Data were analyzed using the FloJo software version 10.1.1 (FlowJo LLC). Each experiment was performed in triplicate and repeated three times.

**Mitochondrial respiratory chain complex I activity.** Enzymatic activities of complex I were determined spectrophotometrically as described in a previous study (23). Mitochondrial respiratory chain complex I activity was calculated as the rotenone-sensitive rate of nicotinamide adenine dinucleotide oxidation ( $\epsilon=6180$  M<sup>-1</sup> at 340 nm). Each experiment was performed in triplicate and repeated three times.

**Blocking the Wnt/ $\beta$ -catenin signaling pathway using inhibitor XAV-939.** OB-6 cells were treated with tankyrase inhibitor XAV-939 (10  $\mu$ M; Abcam) for 30 min followed by addition of H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M) or H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M) + isoporsoralen (1  $\mu$ M) for 24 h. The control was treated with just the media. Cell apoptosis, ROS production and calcium accumulation were then evaluated as described above. Each experiment was performed in triplicate and repeated three times.

**Statistical analysis.** Data are presented as the mean  $\pm$  standard deviation. SPSS version 17.0 software (SPSS, Inc.) was used to process data. The comparisons between groups were performed using one-way ANOVA and Tukey's honestly




Figure 1. Isopsoralen inhibits H<sub>2</sub>O<sub>2</sub>-induced apoptosis. (A) Cell viability and (B) apoptotic rate were analyzed. \*P<0.05 or \*\*P<0.01, with comparisons indicated by lines. H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide.

significant difference post hoc test. P<0.05 was considered to indicate statistical significance.

## Results

**Isopsoralen inhibits H<sub>2</sub>O<sub>2</sub>-induced apoptosis in osteoblastic OB-6 cells.** Osteoblastic OB-6 cell viability was examined by XTT assay. Results indicated that cell viability was significantly inhibited by H<sub>2</sub>O<sub>2</sub> compared with the control, in a time-dependent manner (P<0.05; Fig. 1A). Isopsoralen significantly ameliorated cell viability in H<sub>2</sub>O<sub>2</sub>-treated OB osteoblastic cells (P<0.05; Fig. 1A). Subsequently, the apoptotic rate was examined by flow cytometry. Results indicated that there was a significantly increase in the apoptotic rate in H<sub>2</sub>O<sub>2</sub>-treated cells compared with the control group (P<0.05; Fig. 1B). By contrast, H<sub>2</sub>O<sub>2</sub>-induced apoptosis was significantly inhibited by isopsoralen (P<0.01; Fig. 1B).

**Isopsoralen protects cell mitochondrial function in H<sub>2</sub>O<sub>2</sub>-treated osteoblastic OB-6 cells.** When compared with the control group, a significant downregulation in ROS production was detected in H<sub>2</sub>O<sub>2</sub>-treated OB-6 cells at 12, 24 and 48 h. Of note, treatment with isopsoralen significantly reduced H<sub>2</sub>O<sub>2</sub>-mediated ROS production (P<0.01; Fig. 2A). In addition, the activity of complex I was examined following treatment with H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub> + isopsoralen. It was identified that complex I activity decreased significantly in the H<sub>2</sub>O<sub>2</sub>-treated cells, but isopsoralen significantly reversed the effects induced by H<sub>2</sub>O<sub>2</sub> (P<0.01; Fig. 2B). These findings suggested that isopsoralen protected the OB-6 osteoblast mitochondrial function following treatment with H<sub>2</sub>O<sub>2</sub>.

**Isopsoralen restores bone formation in H<sub>2</sub>O<sub>2</sub>-treated osteoblastic OB-6 cells.** Calcium accumulation was




Figure 2. Isopsoralen protects against H<sub>2</sub>O<sub>2</sub>-induced mitochondrial dysfunction. (A) Levels of ROS and (B) activity of complex I OB-6 osteoblastic cells were measured. \*P<0.05 or \*\*P<0.01, with comparisons indicated by lines. H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; ROS, reactive oxygen species.

significantly reduced by H<sub>2</sub>O<sub>2</sub>, and this effect was reversed by treatment with isopsoralen at all time-points (P<0.01; Fig. 3A). Furthermore, isopsoralen significantly promoted osteogenic gene expression (OCN and RUNX2) in H<sub>2</sub>O<sub>2</sub>-treated osteoblasts (P<0.01; Fig. 3B and C). These results further supported the hypothesis that isopsoralen reduced the damage to bone formation following H<sub>2</sub>O<sub>2</sub> treatment.

**Isopsoralen activates the intracellular Wnt/β-catenin signaling pathway in H<sub>2</sub>O<sub>2</sub>-treated osteoblastic OB-6 cells.** To identify the cytoprotective mechanism of isopsoralen, the activation of the Wnt/β-catenin signaling pathway was investigated. The effect of isopsoralen on the protein expression of Wnt, β-catenin and tankyrase in H<sub>2</sub>O<sub>2</sub>-treated and non-H<sub>2</sub>O<sub>2</sub>-treated osteoblastic OB-6 cells was determined (Fig. 4A). It was demonstrated that β-catenin and tankyrase expression were significantly decreased in osteoblastic OB-6 cells treated with H<sub>2</sub>O<sub>2</sub> compared with the control group (P<0.01; Fig. 4B). When compared with the H<sub>2</sub>O<sub>2</sub>-treated cells, the isopsoralen treatment promoted the expression of β-catenin and tankyrase (P<0.01; Fig. 4B), whilst isopsoralen + H<sub>2</sub>O<sub>2</sub> treatment also significantly increased β-catenin and tankyrase protein expression. There was no difference in Wnt expression between the four treatment groups (P>0.05; Fig. 4B). These results suggested that isopsoralen activated the Wnt/β-catenin signaling pathway and was able to attenuate H<sub>2</sub>O<sub>2</sub>-induced Wnt/β-catenin signal inhibition in osteoblastic OB-6 cells.




Figure 3. Isopsoralen protects against H<sub>2</sub>O<sub>2</sub>-induced suppression of bone formation. (A) Calcium accumulation, (B) OCN expression and (C) RUNX2 expression were determined. \*\*P<0.01, with comparisons indicated by lines. H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; OCN, osteocalcin; RUNX2, runt-related transcription factor 2.




Figure 4. Isopsoralen activates the Wnt/β-catenin pathway. (A) Protein expression of tankyrase, Wnt and β-catenin was analyzed by Western blot analysis. (B) Western blot results were analyzed quantitatively. \*\*P<0.01, with comparisons indicated by lines. H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide.






Figure 5. Activation of the Wnt/ $\beta$ -catenin pathway is required for isopsoralen-induced protection against  $H_2O_2$ . (A) The expression of tankyrase, (B) cell apoptotic rate, (C) ROS production and (D) calcium accumulation were analyzed. \*\* $P < 0.01$ , with comparisons indicated by lines.  $H_2O_2$ , hydrogen peroxide; ROS, reactive oxygen species.

*The Wnt/ $\beta$ -catenin signaling pathway is the target for isopsoralen in  $H_2O_2$ -treated osteoblastic OB-6 cells.* To identify the role of the Wnt/ $\beta$ -catenin signaling pathway in osteoblastic OB-6 cells, cells were pretreated with 10  $\mu M$  inhibitor XAV-939 for 30 min then treated with  $H_2O_2$  or isopsoralen +  $H_2O_2$  for 24 h. OB-6 cells treated with XAV-939 demonstrated an obvious decrease in tankyrase protein expression which confirmed the inhibitory effect of XAV-939. Furthermore, following the XAV-939 pretreatment, there was no significant difference in cell apoptosis ( $P > 0.05$ ; Fig. 5B), ROS production ( $P > 0.05$ ; Fig. 5C) or calcium accumulation ( $P > 0.05$ ; Fig. 5D) between the  $H_2O_2$ -treated group and isopsoralen +  $H_2O_2$ -treated group. Therefore, isopsoralen inhibited the apoptotic rate and protected the mitochondrial function and bone formation in  $H_2O_2$ -treated OB-6 cells via activation of the Wnt/ $\beta$ -catenin signaling pathway.

## Discussion

Osteoporosis increases the risk of bone fractures and other complications, and affects >200 million people worldwide (24). To date, studies investigating the cellular effects and molecular mechanisms of isopsoralen for osteoporosis treatment are limited. The present study demonstrated that isopsoralen had protective effects against oxidative stress

induced by  $H_2O_2$ , indicated by the increased cell proliferation, mitochondrial function and bone formation compared with the  $H_2O_2$ -treated cells. It was also identified that isopsoralen activated the Wnt/ $\beta$ -catenin signaling pathway.

Osteoblasts are crucial in bone formation and remodeling (25). For a number of years, numerous research teams have focused on identifying novel molecular targets to promote osteoblast cell survival (26).  $H_2O_2$  induces osteoblastic cell apoptosis and also impairs osteoblast differentiation (27,28). Therefore,  $H_2O_2$  is often used *in vitro* to establish a cellular model of osteonecrosis (29). A previous study determined that intraperitoneal injection of isopsoralen at 5 and 10 mg/kg per day for two weeks significantly enhanced the hind limb locomotor function of mice with bone damage. The same study also identified significant anti-apoptotic activity of isopsoralen by regulating the PI3K/AKT pathway (30). Isopsoralen at concentrations of  $1 \times 10^{-5}$  mol/l effectively inhibits  $H_2O_2$ -induced damage to human lens epithelial cells through upregulating two mitochondrial protein spots (with m/z of 6532 and 6809) (31). The present study identified that  $H_2O_2$  treatment inhibited OB-6 osteoblastic cell proliferation and induced cell apoptosis. By contrast, isopsoralen treatment promoted cell survival and protected against the damage induced by  $H_2O_2$ . However, cell proliferation was only investigated

using the XTT method due to the limited financial support for this investigation.

The equilibrium between the formation and resorption of bone exerts a crucial role in modulating bone mass in osteoporosis (32). The present study demonstrated that isopsoralen promoted calcium accumulation, and also OCN and RUNX2 mRNA expression following H<sub>2</sub>O<sub>2</sub> treatment which indicated that isopsoralen enhanced bone formation in OB-6 cells. Previous *in vivo* and *in vitro* studies suggested that isopsoralen had osteoprotective effects. For example, following administration of isopsoralen (10 and 20 mg/kg for 8 weeks) to sex hormone-deprived mice, osteoporosis symptoms were ameliorated with mice displaying increased bone strength and improved trabecular bone microstructure (14). In nude rats with osteosarcoma, isopsoralen and psoralen treatment induced growth inhibitory effects on transplanted tumors, and caused apoptosis or necrosis of osteosarcoma without significant toxic effects (15). Isopsoralen suppresses bone BMSCs proliferation in a dose-dependent manner whilst significantly enhancing osteogenesis as determined by the promotion of alkaline phosphatase (ALP) activity, calcium salt sediment yield, and basic fibroblast growth factor, insulin-like growth factor-1, sp7 transcription factor and runx-2 mRNA expression (16). A recent study by Wang *et al* (33) examined the influence of isopsoralen on the differentiation of MSCs into osteoblasts as well as its effect on bone formation under osteoporotic conditions. Results suggested that isopsoralen promoted BMSC differentiation into osteoblasts due to upregulated ALP, OCN and RUNX2 expression. In addition, bone parameters including trabecular thickness, bone volume and trabecular number in the distal femoral metaphysis were significantly increased in ovariectomized mice following intragastrical administration with isopsoralen. These findings suggest that isopsoralen has potential functions in preventing and treating osteoporosis. The present study demonstrated that treatment with isopsoralen increased OCN and RUNX2 mRNA expression, as well as calcium deposition in OB-6 osteoblastic cells.

ROS are unavoidable by-products of oxidative stress with the concentration determining the influence on cells. ROS at low concentration activates gene expression in cells, but ROS at high concentration damages lipids, proteins and nuclear acids, and therefore is harmful to cells (34). During homeostasis, ROS levels are strictly controlled by antioxidant enzymes, but this equilibrium is disturbed under oxidative stress (35,36). It has been determined that ROS production in mitochondria is promoted under environmental stimuli and this dramatically affects cell growth (37-39). The present study determined that H<sub>2</sub>O<sub>2</sub>-induced stress promoted ROS production and inhibited complex I activity in cultured OB-6 cells. Isopsoralen protected mitochondrial damage induced by H<sub>2</sub>O<sub>2</sub> via downregulating ROS production and upregulating complex I activity. ROS is crucial in osteoporosis development with increased ROS production induced by oxidative stress, leading to osteoblast cell damage and apoptosis (40,41). **Furthermore, ROS accelerates apoptosis of osteoblasts, inhibits their differentiation and impairs bone formation (42,43). The present findings demonstrated that isopsoralen protected mitochondrial functions in OB cells subjected to oxidative stress through inhibiting ROS production.**

To the best of our knowledge, the present study provided the first evidence that isopsoralen attenuated H<sub>2</sub>O<sub>2</sub>-induced damage in oxidatively challenged OB-6 osteoblasts via the Wnt/ $\beta$ -catenin signaling pathway. It was demonstrated that isopsoralen activated the Wnt/ $\beta$ -catenin signaling pathway due to the promotion of  $\beta$ -catenin and tankyrase expression, but no significant effects on Wnt expression. Tankyrase and  $\beta$ -catenin are the main transducers of the Wnt/ $\beta$ -catenin pathway, and therefore alterations in their expression levels demonstrated the effect of isopsoralen on the Wnt/ $\beta$ -catenin signaling pathway. The recent characterization of the Wnt/ $\beta$ -catenin signaling pathway in the regulation of osteoblast proliferation and differentiation provided important insights into understanding of bone metabolism pathophysiology (44). For example, the Wnt/ $\beta$ -catenin signaling pathway serves an essential role in bone formation, regeneration, modeling and remodeling by stimulating the proliferation and differentiation of osteoblasts, and also due to its role in the response of bone to mechanical loading (45-47). Nuclear accumulation of stabilized  $\beta$ -catenin is an important indicator of osteoblast differentiation (48,49). Inactivation of Axin2, a negative regulator of the Wnt/ $\beta$ -catenin pathway, promotes osteoblast proliferation and differentiation, as well as matrix mineralization *in vitro* and *in vivo* (50). Activation of the Wnt/ $\beta$ -catenin pathway enhances Runx2 expression, which is a crucial transcription factor for osteoblast differentiation (51). Therefore, the discovery and development of new drugs that activate the Wnt/ $\beta$ -catenin pathway is a promising approach for the development of novel osteoporosis therapies. In conclusion, the present findings demonstrated that isopsoralen protected against damage induced by H<sub>2</sub>O<sub>2</sub> in OB-6 cells, indicated by decreased apoptosis, and increased mitochondrial function and bone formation. Furthermore, it was identified that the Wnt/ $\beta$ -catenin signaling pathway may be the underlying signaling pathway involved in this process. The current study was conducted using only the cultured cell line OB-6, therefore future study into the effects of isopsoralen will involve other cell lines and *in vivo* work to fully elucidate the underlying mechanism of action. However, the present results did provide evidence for the development of novel therapeutic approaches involving isopsoralen for bone-related disease treatment.

#### Acknowledgements

Not applicable.

#### Funding

No funding was received.

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### Authors' contributions

YPL was guarantor of the current study and designed the study, performed the data analysis and experimental studies,

and prepared and edited the manuscript. BW performed the statistical analysis. FL and JL researched the literature and acquired the data. JL also reviewed and revised manuscript. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

- Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. *Lancet* 377: 1276-1287, 2011.
- Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA and Center JR: Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA* 301: 513-521, 2009.
- Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H and Eder IE: The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. *Nutrients* 6: 4491-4519, 2014.
- Tuck SP and Datta HK: Osteoporosis in the aging male: Treatment options. *Clin Interv Aging* 2: 521-536, 2007.
- Khosla S: Update in male osteoporosis. *J Clin Endocrinol Metab* 95: 3-10, 2010.
- Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, Shi Q, Cui XJ and Wang YJ: Chinese herbal medicine for osteoporosis: A systematic review of randomized controlled trials. *Evid. Based. Complement. Alternat. Med* 2013: 356260, 2013.
- Uebelhart D, Frey D, Frey-Rindova P, Goerres G and Michel BA: Therapy of osteoporosis: Bisphosphonates, SERM's, teriparatide and strontium. *Z Rheumatol* 62: 512-517, 2003 (In German).
- Wang Y, Hong C, Zhou C, Xu D and Qu HB: Screening antitumor compounds Psoralen and Isopsoralen from *Psoralea corylifolia* L. Seeds. *Evid Based Complement Alternat Med* 2011: 363052, 2011.
- Wu CR, Chang CL, Hsieh PY, Lin LW and Ching H: Psoralen in isopsoralen, two coumarins of *Psoraleae Fructus*, can alleviate scopolamine-induced amnesia in rats. *Planta Med* 73: 275-278, 2007.
- Yang Z, Huang JH, Liu SF, Zhao YJ, Shen ZY, Wang YJ and Bian Q: The osteoprotective effect of psoralen in ovariectomy-induced osteoporotic rats via stimulating the osteoblastic differentiation from bone mesenchymal stem cells. *Menopause* 19: 1156-1164, 2012.
- Tang DZ, Yang F, Yang Z, Huang J, Shi Q, Chen D and Wang YJ: Psoralen stimulates osteoblast differentiation through activation of BMP signaling. *Biochem Biophys Res Commun* 405: 256-261, 2011.
- Tsai MH, Huang GS, Hung YC, Bin L, Liao LT and Lin LW: *Psoralea corylifolia* extract ameliorates experimental osteoporosis in ovariectomized rats. *Am J Chin Med* 35: 669-680, 2007.
- Wong RW and Rabie AB: Effect of psoralen on bone formation. *J Orthop Res* 29: 158-164, 2011.
- Yuan X, Bi Y, Yan Z, Pu W, Li Y and Zhou K: Psoralen and Isopsoralen ameliorate sex hormone deficiency-induced osteoporosis in female and male mice. *Biomed Res Int* 2016: 6869452, 2016.
- Lu H, Zhang L, Liu D, Tang P and Song F: Isolation and purification of psoralen and isopsoralen and their efficacy and safety in the treatment of osteosarcoma in nude rats. *Afr Health Sci* 14: 641-647, 2014.
- Ming L, Ge B, Chen K, Ma H and Zhai Y: Effects of isopsoralen on bone marrow stromal stem cells differentiate and proliferate in vitro. *Zhongguo Zhong Yao Za Zhi* 36: 2124-2128, 2011 (In Chinese).
- Neben CL and Merrill AE: Signaling pathways in craniofacial development: Insights from rare skeletal disorders. *Curr Top Dev Biol* 115: 493-542, 2015.
- Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, Davidson JM, Rottman J, Lee E and Young PP: The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. *Proc Natl Acad Sci USA* 105: 18366-18371, 2008.
- Lorenzon A, Calore M, Poloni G, De Windt LJ, Braghetta P and Rampazzo A: Wnt/ $\beta$ -catenin pathway in arrhythmogenic cardiomyopathy. *Oncotarget* 8: 60640-60655, 2017.
- Burgers TA and Williams BO: Regulation of Wnt/ $\beta$ -catenin signaling within and from osteocytes. *Bone* 54: 244-249, 2013.
- Duan P and Bonewald LF: The role of the wnt/ $\beta$ -catenin signaling pathway in formation and maintenance of bone and teeth. *Int J Biochem Cell Biol* 77: 23-29, 2016.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Skemiene KJ and Liobikas V: Borutaite. Anthocyanins as substrates for mitochondrial complex I- protective effect against heart ischemic injury. *FEBS J* 282: 963-971, 2015.
- Schurman L, Bagur A, Claus-Hermberg H, Messina OD, Negri AL, Sánchez A, González C, Diehl M, Rey P, Gamba J, *et al*: Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012. *Medicina (B Aires)* 73: 55-74, 2013 (In Spanish).
- Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, Doan P, Chi JT, Salter AB, Lento WE, Reya T, *et al*: Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. *Nat Med* 16: 475-482, 2010.
- Guo S, Xie Y, Fan JB, Ji F, Wang S and Fei H: A-Melanocyte stimulating hormone attenuates dexamethasone-induced osteoblast damages through activating melanocortin receptor 4-SphK1 signaling. *Biochem Biophys Res Commun* 469: 281-287, 2016.
- Liu H, Bian W, Liu S and Huang K: Selenium protects bone marrow stromal cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation by suppressing oxidative stress and ERK signaling pathway. *Biol Trace Elem Res* 150: 441-450, 2012.
- Yang Y, Su Y, Wang D, Chen Y, Wu T, Li G, Sun X and Cui L: Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation via Wnt/FoxO3a signaling. *Oxid Med Cell Longev* 2013: 351895, 2013.
- Liang D, Xiang L, Yang M, Zhang X, Guo B, Chen Y, Yang L and Cao J: ZnT7 can protect MC3T3-E1 cells from oxidative stress-induced apoptosis via PI3K/Akt and MAPK/ERK signaling pathways. *Cell Signal* 25: 1126-1135, 2013.
- Li XM, Yang Q, Li XB, Cheng Q, Zhang K, Han J, Zhao JN, Liu G and Zhao MG: Estrogen-like neuroprotection of isopsoralen against spinal cord injury through estrogen receptor ER $\alpha$ . *Metab Brain Dis* 32: 259-265, 2017.
- Feng CJ, Huang XR, Qi MX, Tang SW, Hu YH, Chen S and Ke FY: Mitochondrial proteomic analysis of isopsoralen protection against oxidative damage in human lens epithelial cells. *Chin J Integr Med* 18: 529-533, 2012.
- Manolagas SC: Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr Rev* 21: 115-137, 2000.
- Wang J, Li SF, Wang T, Sun CH, Wang L, Huang MJ, Chen J, Zheng SW, Wang N, Zhang YJ and Chen TY: Isopsoralen-mediated suppression of bone marrow adiposity and attenuation of the adipogenic commitment of bone marrow-derived mesenchymal stem cells. *Int J Mol Med* 39: 527-538, 2017.
- Son Y, Kim S, Chung HT and Pae HO: Reactive oxygen species in the activation of MAP kinases. *Methods Enzymol* 528: 27-48, 2013.
- Andreyev AY, Kushnareva YE, Murphy AN and Starkov AA: Mitochondrial ROS metabolism: 10 years later. *Biochemistry (Mosc)* 80: 517-531, 2015.
- Mailloux RJ: Teaching the fundamentals of electron transfer reactions in mitochondria and the production and detection of reactive oxygen species. *Redox Biol* 4: 381-398, 2015.
- Brand MD: Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. *Free Radic Biol Med* 100: 14-31, 2016.
- Reczek CR and Chandel NS: ROS-dependent signal transduction. *Curr Opin Cell Biol* 33: 8-13, 2015.
- Kowaltowski AJ, de Souza-Pinto NC, Castilho RF and Vercesi AE: Mitochondria and reactive oxygen species. *Free Radic Biol Med* 47: 333-343, 2009.

40. Herbst RS: Review of epidermal growth factor receptor biology. *Int J Radiat Oncol Biol Phys* 59 (Suppl 2): S21-S26, 2004.
41. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PØ, Eskilsson E, *et al*: EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. *Acta Neuropathol* 125: 683-698, 2013.
42. Li J, He W, Liao B and Yang J: FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. *Sci Rep* 5: 12724, 2015.
43. She C, Zhu LQ, Zhen YF, Wang XD and Dong QR: Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: New implications for osteonecrosis treatment? *Cell Signal* 26, 1-8, 2014.
44. Krishnan V, Bryant HU and Macdougald OA: Regulation of bone mass by wnt signaling. *J Clin Invest* 116: 1202-1209, 2006.
45. Valenta T, Hausmann G and Basler K: The many faces and functions of  $\beta$ -catenin. *EMBO J* 31: 2714-2736, 2012.
46. Rossini M, Gatti D and Adami S: Involvement of WNT/ $\beta$ -catenin signaling in the treatment of osteoporosis. *Calcif Tissue Int* 93: 121-132, 2013.
47. Baron R and Kneissel M: WNT signaling in bone homeostasis and disease: From human mutations to treatments. *Nat Med* 19: 179-192, 2013.
48. Baron R, Rawadi G and Roman-Roman S: Wnt signaling: A key regulator of bone mass. *Curr Top Dev Biol* 76: 103-127, 2006.
49. Zhang J, Zhang X, Zhang L, Zhou F, van Dinther M and Ten Dijke P: LRP8 mediates Wnt/ $\beta$ -catenin signaling and controls osteoblast differentiation. *J Bone Miner Res* 27: 2065-2074, 2012.
50. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, Birchmeier W and Hsu W: The role of Axin2 in calvarial morphogenesis and craniosynostosis. *Development* 132: 1995-2005, 2005.
51. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. *J Biol Chem* 280: 33132-33140, 2005.